|
|||||
![]() |
|
Home healthcare provider Addus HomeCare (NASDAQ:ADUS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 21.8% year on year to $349.4 million. Its non-GAAP profit of $1.49 per share was 1.8% above analysts’ consensus estimates.
Is now the time to buy ADUS? Find out in our full research report (it’s free).
Addus HomeCare’s second quarter saw a significant positive reaction from the market, driven by outperformance on both revenue and adjusted profit compared to Wall Street expectations. Management attributed the strong results to continued momentum in personal care hiring, robust execution in the recently acquired Gentiva operations, and favorable reimbursement trends in large states such as Illinois and Texas. CEO Dirk Allison emphasized that personal care volume growth and strategic acquisitions like Gentiva and Helping Hands were key contributors, stating, “We are confident that personal care services continue to deliver real value to state Medicaid programs as well as our managed care partners.”
Looking ahead, Addus HomeCare’s management believes revenue growth will be supported by recently legislated reimbursement rate increases in Illinois and Texas and ongoing expansion through targeted acquisitions. CFO Brian Poff noted, “We expect to benefit from additional rate increases in Illinois and Texas,” while COO Brad Bickham highlighted further rollout of digital caregiver tools and the potential for additional state-level rate improvements. However, management also acknowledged ongoing challenges in clinical hiring and the risk of future federal payment reductions in home health, with Allison cautioning that “the proposed home health rule will most likely continue to delay any meaningful home health opportunities.”
Management identified strong personal care growth, state reimbursement increases, and successful integration of recent acquisitions as primary drivers of the quarter’s results.
Addus expects reimbursement rate increases, ongoing acquisitions, and operational enhancements to underpin revenue and margin stability, but faces headwinds from regulatory uncertainty and labor constraints.
Looking ahead, the StockStory team will be monitoring (1) the implementation and impact of state reimbursement increases in Illinois and Texas, (2) continued expansion through acquisitions like Helping Hands and integration of clinical services, and (3) progress with digital caregiver tools in additional markets. We will also track regulatory developments around Medicare payment rules, which remain a significant variable for home health segment performance.
Addus HomeCare currently trades at $113.25, up from $107.13 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Sep-12 | |
Aug-13 | |
Aug-13 | |
Aug-07 | |
Aug-04 | |
Aug-04 | |
Aug-04 | |
Aug-04 | |
Aug-04 | |
Aug-04 | |
Aug-02 | |
Jul-29 | |
Jul-21 | |
Jul-09 | |
Jul-08 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite